MedTrace Logo

Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)

NCT01254318 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2016-11-02

Study results available
· View outcomes & findings →

Summary

This will be a retrospective study that includes retrospective chart reviews at major institutions across Canada. The intent of the study is to generate both regional and national incidence data for non-Candida invasive fungal infections (IFI) in high risk participants. The study will include participants receiving stem cell transplant and high dose chemotherapy treatment for leukemia.

Conditions

Interventions

OTHER

Standard Care

Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-11-30
Completion
2014-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01254318 on ClinicalTrials.gov